Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- (-) High-Deductible Health Plans
- (-) Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- (-) Real-World Evidence
- (-) Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 105 Results
NPC Submits Comments on Cures 2.0
The National Pharmaceutical Council (NPC) submitted comments in response to a public request for input on Cures 2.0, an “effort to modernize coverage and access to life-saving cures in the United…
NPC Weighs in on CMS Oncology Care First Model
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
New Study Reveals Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
When the health care community talks about evidence-based medicine, it’s usually in the context of efforts to ensure clinicians are delivering treatments to patients that align with the best…
Good News for Patients With High-Deductible Health Plans
In his commentary for Specialty Pharmacy Times, NPC President and CEO Dan Leonard explains how research supported by NPC and conducted by VBID Health demonstrates the health and cost benefits of…
Best Ideas Aren’t Always (or Often) From Washington
In his latest commentary for Chain Drug Review, National Pharmaceutical Council President and CEO Dan Leonard explores the health care concerns and ideas for improvement discussed at recent regional…
Uptake and Federal Budgetary Impact of Allowing Health Savings Account-eligible High Deductible Health Plans to Cover Chronic Disease Drugs and Services Pre-deductible
This report examines the net federal budgetary impact allowing Health Savings Account-eligible HDHPs to expand pre-deductible coverage to include chronic disease services.
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
Six Ways to Make Real-world Evidence Methods More Transparent
Acceptance of studies based on “real-world data” remains limited, partly because the research methods used to generate usable evidence are not always transparent. That perception could change thanks…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…
Patient-Community Perspectives on Real-World Evidence: Enhancing Engagement, Understanding, and Trust
Researchers found that while most patient organizations were initially unaware of real-world evidence (RWE) and its actual or potential uses, they recognized the ability of RWE to provide relevant…
Patients on RWE: WIIFM? (What’s In It for Me?)
In an article published in The Patient, NPC and the National Health Council found that while most patients were initially unaware of real-world evidence (RWE) and its actual or potential uses,…
NPC in Chain Drug Review: Preserving the Proven Impact of Biopharmaceutical Innovation
In his latest commentary for Chain Drug Review, NPC President and Chief Executive Officer Dan Leonard considers the challenges in measuring and paying for value in health care, particularly when it…
NPC in Morning Consult: Does High Return Call for Greater Investment?
In his latest commentary for Morning Consult, NPC Chief Science Officer Robert W. Dubois explores new research that sheds light on which types of medical care have provided the greatest overall…
FDA Clarifies What Information Can Be Exchanged With Health Decision-Makers
With the release of two guidance documents this week, the US Food and Drug Administration took significant steps to modernize how health care information is communicated. The final guidance released…
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
What’s Next in Precision Medicine?
Personalized medicine is greatly changing health care practices, as well as how innovative treatments are being developed.
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
National Pharmaceutical Council President Dan Leonard in Specialty Pharmacy Times: How Do We Pay for Medical Innovation?
In this month's Specialty Pharmacy Times, National Pharmaceutical Council President Dan Leonard says it’s time to think differently about how we pay for health care and assess value and benefits.